Cancer Treatment Options: How to Choose What's Right

Cancer treatment options are not a single path — they are a set of evidence-based choices that oncologists and patients weigh together, based on cancer type, stage, grade, biomarker profile, patient fitness, and personal values. Understanding how these options are evaluated, ranked, and compared is as important as understanding how each treatment works. The cancer treatment guide on this site explains how surgery, chemotherapy, immunotherapy, and targeted therapy function. This guide answers a different question: when multiple options exist, how do you choose?

The answer is rarely “one option is obviously right.” The ProtecT trial enrolled 1,643 men with localized prostate cancer and found no difference in cancer-specific survival between surgery, radiation, and active monitoring at 10 years. Three very different treatments — the same oncologic outcome. Choosing between cancer treatment options often requires this level of granular, evidence-based comparison.

Category 1 NCCN’s highest evidence rank — the guideline-recommended standard of care, supported by randomized trial data

10 yrs ProtecT trial follow-up — no cancer-specific survival difference between surgery, radiation, and active monitoring for localized prostate cancer

11.6 vs 8.9 mo Median OS with early palliative care added to standard oncology vs. standard oncology alone (Temel, NEJM 2010)

16.5 vs 8.2 mo PFS for pembrolizumab vs. chemotherapy first-line in MSI-H metastatic CRC (KEYNOTE-177)

How Oncologists Rank Cancer Treatment Options

Oncology decisions follow published evidence and expert consensus guidelines from organizations that systematically review clinical trial data. The National Comprehensive Cancer Network (NCCN) publishes tumor-specific treatment guidelines used by oncologists across the US — and ranks treatment options by evidence quality:

Category	Meaning	Clinical Implication
Category 1	Uniform consensus based on high-level evidence (randomized controlled trials)	Preferred standard of care
Category 2A	Uniform consensus based on lower-level evidence (expert opinion, retrospective data)	Appropriate first-line option
Category 2B	Non-uniform consensus, lower-level evidence	Acceptable when higher-evidence options aren’t suitable
Category 3	Major disagreement among NCCN expert panel members	Generally not recommended

NCCN Category 1 options exist for most common cancers — these are treatments supported by Phase III randomized controlled trials. When multiple Category 1 options exist for the same cancer, shared decision-making between oncologist and patient becomes essential. NCCN makes patient versions of its guidelines freely available at nccn.org/patients.

ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) publish complementary guidelines. When NCCN, ASCO, and ESMO all endorse the same option, the evidence base is strongest. When guidelines diverge, it signals genuine clinical equipoise — and a reason to consider a cancer second opinion.

Key Factors That Determine Your Treatment Options

Not all treatment options apply to all patients. Your specific set of options is shaped by a constellation of factors:

Factor	How It Affects Options
Cancer type and subtype	Different tumors have entirely different treatment algorithms — a lung cancer plan shares nothing with a lymphoma plan, even at the same stage
Stage (I–IV)	Determines whether curative intent is achievable; what surgery is possible; whether systemic therapy is needed. See cancer staging guide
Grade (1–3)	Influences treatment intensity — Grade 3 breast cancer often requires chemotherapy regardless of Stage; Grade 1 may not. See cancer grade guide
Biomarker profile	Opens or closes targeted therapy options; determines immunotherapy eligibility (MSI-H, PD-L1, TMB, EGFR, ALK, HER2, BRCA)
ECOG Performance Status (PS)	Full-intensity treatment requires PS 0–1; PS 2 often limits regimen intensity; PS 3–4 typically limits to supportive care
Organ function	Cardiac, renal, hepatic function limit certain drugs — cisplatin requires adequate GFR; doxorubicin requires adequate LVEF; taxanes require adequate hepatic function
Patient preferences	Fertility preservation, quality of life priorities, cultural and religious values, fear of specific side effects — all legitimate clinical factors
Prior treatment history	What has already been tried; known resistance mechanisms; cumulative drug toxicity limits (e.g., anthracycline lifetime dose)

ECOG Performance Status

The Eastern Cooperative Oncology Group (ECOG) Performance Status scale is used in virtually all oncology clinical trials and routine treatment decisions to assess patient fitness:

PS 0 Fully active — all treatments appropriate
PS 1 Restricted in physically strenuous activity but ambulatory — most treatments appropriate
PS 2 Ambulatory and capable of self-care, but unable to carry out work activities; up and about >50% of waking hours — reduced-intensity treatment often required
PS 3 Limited self-care capacity; confined to bed or chair >50% of waking hours — typically only supportive therapies
PS 4 Completely disabled — palliative and supportive care only

Most Phase III clinical trials require PS 0–1 for enrollment. Understanding your PS helps explain why certain options on a clinical trial may not be accessible to all patients.

Active Surveillance — When Watching Is the Right Option

For some cancers, the evidence-supported option is not to treat immediately — it is to watch carefully and treat only if the cancer progresses. Active surveillance (AS) is not the same as neglect. It involves structured monitoring with defined criteria for intervention.

Prostate Cancer (Grade Group 1)

Approximately 60% of prostate cancers diagnosed at biopsy are Grade Group 1 (Gleason 6) — an extremely indolent biology. The ProtecT trial (NEJM 2016) randomized 1,643 men with localized prostate cancer to active monitoring, radical prostatectomy, or radiotherapy. At 10-year follow-up: prostate cancer-specific mortality was under 2% in all three groups — with no statistically significant difference. Active monitoring was associated with higher rates of metastatic disease at 10 years, but overall mortality was equivalent. Side effects differed substantially: surgery caused more urinary incontinence and erectile dysfunction; radiation caused more bowel problems.

Current NCCN guidelines recommend active surveillance as the preferred option for most patients with low-risk, Grade Group 1 prostate cancer. AS involves: PSA every 6–12 months, mpMRI, and periodic repeat biopsy (every 1–3 years or if PSA rises significantly).

Low-Grade Thyroid Microcarcinoma (≤1 cm papillary)

Kuma Hospital in Tokyo followed patients with papillary thyroid microcarcinoma on active surveillance for over a decade. Over 10 years, fewer than 1% of patients developed disease requiring urgent surgery. The American Thyroid Association (ATA) and AACE now support active surveillance for low-risk papillary thyroid microcarcinoma ≤1 cm without high-risk features (lymph node involvement, extrathyroidal extension, proximity to recurrent laryngeal nerve).

Indolent Lymphoma and CLL

Follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia (CLL) are often managed with watchful waiting until symptomatic. Treatment is initiated when defined criteria are met: Rai Stage III-IV in CLL, progressive cytopenias, symptomatic lymphadenopathy, rapidly rising lymphocyte count, or constitutional B symptoms. BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) are the preferred first-line option when treatment becomes necessary.

When Active Surveillance Is NOT Appropriate

Active surveillance is not an option when cancer is aggressive, growing rapidly, causing symptoms, or when the patient has clearly resectable disease with curative-intent surgical options. A thorough discussion with your oncologist — and often a second opinion — is essential before deciding on active surveillance.

Oncology consultation showing a patient reviewing cancer treatment options with a physician — An oncology consultation is where treatment options are reviewed — comparing evidence levels, side effect profiles, clinical trial eligibility, and patient priorities to reach a shared decision.

Treatment Options by Cancer Type

Breast Cancer Treatment Options

The foundational early-stage surgical decision is lumpectomy + radiation vs. mastectomy. Multiple randomized trials beginning with the MILAN trials (1970s–1980s) established equivalent survival — lumpectomy preserves the breast with the same oncologic outcome. The ACOSOG Z0011 trial showed that patients with 1–2 positive sentinel lymph nodes on lumpectomy do not require completion axillary dissection, sparing patients a major surgical procedure.

Adjuvant systemic therapy depends on receptor status:

ER+/HER2-: Endocrine therapy (tamoxifen or aromatase inhibitor) ± chemotherapy, guided by Oncotype DX recurrence score (RS <25: chemotherapy likely not beneficial in postmenopausal; RS ≥26: chemotherapy benefit clear)
HER2+: Trastuzumab-based chemotherapy; T-DM1 for residual disease after neoadjuvant (KATHERINE trial); pertuzumab added for higher-risk patients
Triple-negative (TNBC): Neoadjuvant chemotherapy is standard; pembrolizumab added for high-risk TNBC (KEYNOTE-522, regardless of PD-L1 status); adjuvant olaparib if BRCA1/2-mutated (OlympiA trial)

Metastatic breast cancer: CDK4/6 inhibitor + aromatase inhibitor first-line for HR+/HER2-. T-DXd has transformed HER2-low breast cancer — the DESTINY-Breast04 trial established T-DXd as superior to chemotherapy in HER2-low (IHC 1+ or 2+ without FISH amplification) disease. Sacituzumab govitecan is active in TNBC (ASCENT trial).

Lung Cancer Treatment Options (NSCLC)

Treatment options for metastatic NSCLC are now primarily determined by molecular driver status — making comprehensive biomarker testing mandatory at diagnosis:

EGFR-mutant: Osimertinib first-line (FLAURA: superior OS vs. erlotinib/gefitinib); adjuvant osimertinib for resected EGFR-mutant disease (ADAURA: significantly improved DFS and OS)
ALK-rearranged: Alectinib first-line (ALEX trial: PFS 34 months vs. 10 months with crizotinib)
KRAS G12C: Sotorasib or adagrasib — the first approved KRAS-targeted therapies
No driver mutation, PD-L1 ≥50%: Pembrolizumab monotherapy (KEYNOTE-024)
No driver mutation, PD-L1 <50%: Pembrolizumab + platinum + pemetrexed (KEYNOTE-189) — 3-year OS 31.3% vs. 17.4% chemotherapy alone

Locally advanced (Stage III) NSCLC: Concurrent cisplatin-based chemoradiation followed by consolidation durvalumab (PACIFIC trial: 5-year OS 42.9% vs. 33.4%) — now the standard of care for unresectable Stage III NSCLC.

Prostate Cancer Treatment Options

Options are stratified by NCCN risk group:

Low risk / Grade Group 1: Active surveillance preferred; surgery or radiation for patients electing definitive treatment
Intermediate unfavorable / Grade Group 3: Surgery or radiation + 4–6 months of ADT
High risk / Grade Group 4-5: External beam radiation + 18–36 months of ADT ± abiraterone (STAMPEDE), or radical prostatectomy with pelvic lymph node dissection
Metastatic hormone-sensitive: ADT + abiraterone (LATITUDE) or docetaxel (CHAARTED) or enzalutamide (ARCHES), or triplet: ADT + darolutamide + docetaxel (ARASENS)

Colorectal Cancer Treatment Options

MSI-H metastatic CRC: Pembrolizumab first-line (KEYNOTE-177: PFS 16.5 vs. 8.2 months; OS benefit confirmed) — immunotherapy has transformed first-line options for the ~15% of metastatic CRC patients with MSI-H tumors.

KRAS/NRAS wild-type mCRC: Add cetuximab or panitumumab to FOLFOX/FOLFIRI — but only for left-sided tumors (PRIME, FIRE-3 trials show right-sided CRC does not benefit).

Liver-limited metastases: Resectable colorectal liver metastases offer potential cure — 5-year OS ~30–40% after hepatic metastasectomy. Even initially unresectable metastases can be converted with intensive chemotherapy (FOLFOXIRI ± bevacizumab).

BRAF V600E mCRC: Encorafenib + cetuximab (BEACON CRC trial: significantly improved OS vs. standard second-line chemotherapy).

Head and Neck Cancer Treatment Options

HPV-positive oropharyngeal cancer has a substantially better prognosis than HPV-negative disease, and de-escalation trials (OPTIMA, ECOG-ACRIN 3311, PATHOS) are exploring whether treatment intensity can be reduced without compromising outcomes. Standard of care remains concurrent cisplatin + radiation for locally advanced HPV+ disease. For recurrent/metastatic: pembrolizumab monotherapy or pembrolizumab + platinum + 5-FU first-line (KEYNOTE-048, for CPS ≥1 tumors).

Clinical Trial Options

Clinical trials are not a last resort — they are a treatment option. Phase III trials compare new treatments against the current standard of care; patients in the control arm always receive standard treatment, never placebo alone.

Why Trials Are Treatment Options

Patients on Phase III clinical trials receive either the current standard of care, or a promising treatment that may prove superior. All trial-related treatment, monitoring, and many supportive care costs are covered by the study. Treatments that emerge from trials — KEYNOTE-189, ADAURA, KEYNOTE-177 — become tomorrow’s standard of care.

How to find trials:

Ask your oncologist at diagnosis and at every treatment change — most patients who don’t enroll were simply not told about open trials
Search clinicaltrials.gov by cancer type, stage, prior treatment, and ZIP code
The NCI Cancer Information Service (1-800-4-CANCER) provides trial matching assistance
NCI-designated cancer centers typically offer far more trials than community hospitals — another reason to consider a consultation at a major center

The NCI’s clinical trials information page explains how trial phases work and what to expect as a participant.

Palliative Care as a Treatment Option

Palliative care is a parallel treatment track — not an alternative to cancer-directed therapy, and not synonymous with hospice. Early integration of palliative care alongside standard oncology treatment improves quality of life, manages symptoms, and helps patients make more informed decisions throughout the cancer journey.

The evidence is compelling: the Temel trial (NEJM 2010) randomized patients with newly diagnosed metastatic NSCLC to either standard oncology care or standard care + early palliative care consultation. The early palliative care group had better quality of life, less depression, less aggressive end-of-life care — and paradoxically, longer median overall survival (11.6 vs. 8.9 months). Better symptom control allowed patients to tolerate active treatment more effectively.

ASCO guidelines now recommend early palliative care integration for patients with advanced cancer or high symptom burden. Asking your team about palliative care at diagnosis is not giving up — it is optimizing your ability to complete treatment at the best possible quality of life.

How to Evaluate Competing Treatment Options

When multiple options exist, use these questions to compare them systematically:

What is the evidence level? Is this NCCN Category 1 (randomized trial data) or 2A (expert consensus)? Was there an OS benefit in the trial, or only PFS?
What are the side effects and quality-of-life impacts? Ask specifically about effects that matter to your daily life — fertility, sexual function, bowel/bladder function, cognitive effects, hair loss.
What is the toxicity burden? Some regimens require weekly infusions; others are taken orally. Consider how treatment fits with your life and commitments.
Is there a clinical trial open that might be superior? Ask at every decision point — eligibility criteria change with each line of therapy.
What happens if this option doesn’t work? What second-line options follow each treatment path? Some choices foreclose others.
What would you recommend if this were your family member? This direct question often yields the most personalized clinical judgment from your oncologist.

If options are genuinely contested — particularly for rare cancers, borderline surgical decisions, or newly approved treatments — a cancer second opinion or tumor board review at an NCI-designated center is the right step. For details on what questions to ask at every appointment, see the cancer diagnosis questions guide. Once you decide on a treatment direction, the cancer surgery guide addresses the most common surgical option in detail. According to ASCO’s Cancer.net, informed patients who understand the evidence behind their options are better equipped to participate in decisions and are more satisfied with the treatment they ultimately choose.

Frequently Asked Questions

How do doctors decide which cancer treatment options to recommend?

Oncologists use published clinical practice guidelines — primarily NCCN, ASCO, and ESMO — which rank treatment options by evidence quality. Category 1 options in NCCN guidelines are supported by randomized controlled trial evidence and represent the preferred standard of care. When multiple Category 1 options exist, the choice depends on patient-specific factors: ECOG Performance Status, biomarker profile, organ function, and patient preferences. Ask your oncologist to explain which guideline category your recommended treatment falls into — and what alternatives exist in the same or adjacent categories.

What is the difference between standard of care and experimental treatment?

Standard of care is a treatment supported by clinical trial evidence and endorsed in published guidelines (typically NCCN Category 1). Experimental treatment is a therapy being evaluated in a clinical trial — it has not yet been proven superior to standard care, though it may become so. Patients in Phase III clinical trials who are in the control arm receive standard of care — not a placebo. Off-label use means using an approved drug for an unapproved indication, which may or may not have supporting evidence. The NCCN Patient Guidelines explain what standard of care means for specific cancer types.

When should I choose active surveillance over treatment?

Active surveillance is the evidence-supported option when cancer biology is so indolent that the risks of treatment side effects exceed the cancer risk over the relevant time horizon. The most established indications: Grade Group 1 (Gleason 6) prostate cancer — the ProtecT trial showed no survival difference at 10 years vs. surgery or radiation; low-risk papillary thyroid microcarcinoma (≤1 cm) — Kuma Hospital data shows <1% disease progression requiring urgent surgery over 10 years; and indolent lymphomas (follicular lymphoma, CLL) before symptoms develop. Active surveillance requires structured monitoring with defined criteria for intervention — it is not the same as watchful waiting and is not appropriate for aggressive, growing, or symptomatic cancers.

How do I know if I’m eligible for a clinical trial?

Ask your oncologist at every decision point — most patients who don’t enroll in trials were simply not asked. Eligibility is determined by cancer type and stage, prior treatment history (often trials require a specific number of prior lines), organ function requirements, and geographic proximity to the trial site. You can search clinicaltrials.gov yourself by cancer type and ZIP code. NCI-designated cancer centers offer far more trials than community hospitals — another reason to consider a consultation at a major center. The NCI Cancer Information Service at 1-800-4-CANCER can also help match you to open trials based on your specific diagnosis.

What does NCCN Category 1 mean?

NCCN Category 1 means the treatment is supported by high-level evidence (typically Phase III randomized controlled trials) and there is uniform consensus among the NCCN expert panel that this is an appropriate treatment option — it represents the preferred standard of care. Category 2A means expert consensus supports the option but the underlying evidence is lower-level (retrospective data, Phase II trials, or expert opinion). Category 2B means non-uniform consensus — acceptable when higher-evidence options aren’t suitable. Category 3 means major disagreement and is generally not recommended. When your oncologist recommends a treatment, ask: “Is this an NCCN Category 1 recommendation for my cancer type and stage?”

Is palliative care the same as giving up on treatment?

No — palliative care is not hospice, and it is not an alternative to cancer treatment. It is a parallel supportive care track that focuses on symptom management (pain, nausea, fatigue, anxiety), goals-of-care discussions, and quality-of-life optimization throughout the cancer journey — at any stage, including during curative-intent treatment. ASCO recommends early integration of palliative care for patients with advanced cancer. The landmark Temel trial (NEJM 2010) found that metastatic NSCLC patients who received early palliative care alongside standard chemotherapy lived longer (11.6 vs. 8.9 months), had better quality of life, and had less aggressive end-of-life care than those receiving standard care alone.

National Comprehensive Cancer Network (NCCN) — NCCN Guidelines for Patients
NCI — What Are Clinical Trials?
ASCO/Cancer.net — Making Decisions About Cancer Treatment
Temel JS et al. — Early palliative care in metastatic NSCLC; NEJM 2010
Hamdy FC et al. — ProtecT trial (localized prostate cancer); NEJM 2016
André T et al. — KEYNOTE-177 (pembrolizumab vs. chemotherapy in MSI-H mCRC); NEJM 2020
Wu YL et al. — ADAURA (osimertinib adjuvant for EGFR-mutant NSCLC); NEJM 2020
Peters S et al. — ALEX trial (alectinib vs. crizotinib in ALK+ NSCLC); NEJM 2017

This article is for educational purposes only and does not constitute medical advice. Discuss all cancer treatment option decisions with your oncology care team.

Cancer Treatment Options: How to Choose What’s Right